Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice

References

• Aston, W.J., et al., 2017. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer, 17 (1), 684.
   PubMed Web of Science ®Google Scholar
• Ahn, D.H., et al., 2018. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. International Journal of Cancer, 142 (8), 1671–1675.
   PubMed Web of Science ®Google Scholar
• Anderson, H., et al., 1994. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology, 12 (9), 1821–1826.
   PubMed Web of Science ®Google Scholar
• Baker, S.A., 2009. Gemcitabine impacts histological structure of mice testis and embryonic organs. Pakistan Journal of Biological Sciences, 12 (8), 607–615.
   PubMedGoogle Scholar
• Bancroft, J. D., and Gamble, M. (Eds.). 2008. Theory and practice of histological techniques. Philadelphia, PA: Elsevier Health Sciences.
   Google Scholar
• Choi, Y., et al., 2018. Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: a nationwide retrospective study. Cancer Research and Treatment, 50 (1), 175.
   Web of Science ®Google Scholar
• Coeman, D.C., et al., 2000. A fatal case of cholestatic liver failure probably related to gemcitabine. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 11 (11), 1503
   PubMed Web of Science ®Google Scholar
• Conroy, T., et al., 2016. Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 57, 10–22.
   PubMed Web of Science ®Google Scholar
• Davern, T. L., and Scharschmidt, B. F. 2002. Biochemical Liver Function Tests. In: M.L.C. Friedman and M.H. Sleisenger, eds. Sleisenger and fordtrans' gastrointestinal and liver disease pathophysiology, diagnosis and management. 7th Edn. Atlanta: Elsevier Science.
   Google Scholar
• DeLeve, L. D., 2013. Cancer chemotherapy, drug-induced liver disease. (Review of hepatotoxicity of cancer chemotherapeutic agents) 3rd ed. Amsterdam, Elsevier, p. 541–568. https://livertox.nlm.nih.gov//Gemcitabine.htm
   Google Scholar
• Dobbie, M., et al., 1998. Veno-occlusive disease of the liver induced by gemcitabine. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 9 (6), 681
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company 2011., Gemzar® (gemcitabine HCL) for injection description. IN 46285, Indianapolis, USA.
   Google Scholar
• Elmore, S., 2007. Apoptosis: a review of programmed cell death. Toxicologic Pathology, 35 (4), 495–516.
   PubMed Web of Science ®Google Scholar
• Germoush, M. O., 2009. Developmental toxicity and cytogenetic effects of the anti-cancer drug gemcitabine, on the embryos of laboratory mice.
   Google Scholar
• Glinsukon, T., et al., 1986. Acute toxicity of nimbolide and nimbic acid in mice, rats and hamsters. Toxicology Letters, 30 (2), 159–166.
   PubMed Web of Science ®Google Scholar
• Guicciardi, M.E., and Gores, G.J., 2005. Apoptosis: a mechanism of acute and chronic liver injury. Gut, 54 (7), 1024–1033. ‏
   PubMed Web of Science ®Google Scholar
• Habeebu, S.S., et al., 1998. Cadmium-induced apoptosis in mouse liver. Toxicology and Applied Pharmacology, 149 (2), 203–209.
   PubMed Web of Science ®Google Scholar
• Hamed, S.S., et al., 2013. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemotherapy and Pharmacology, 72 (3), 553–563.
   PubMed Web of Science ®Google Scholar
• Hassoun, E. A., and Stohs, S. J. 1995. Chromium induced production of reactive oxygen species, DNA single-strand breaks, nitric oxide production, and lactate dehydrogenase leakage in J774A.1 cell cultures. Journal of Biochemical Toxicology, 10, 315–321.
   PubMedGoogle Scholar
• Hryciuk, B., et al., 2018. Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation. Oncology Letters, 15 (2), 1912–1916.
   PubMed Web of Science ®Google Scholar
• Kamer, E., et al., 2003. Effects of intraperitoneal administration of gemcitabine and paclitaxel on hepatic regeneration in rats. The Turkish Journal of Gastroenterology, 14 (1), 1–6.
   PubMedGoogle Scholar
• Keller, K. A., and Banks, C., 2006. Multidose general toxicology studies. In: Toxicological testing handbook: principles, applications and data interpretation. New York, NY: Informa Healthcare USA, Inc, 149–181.
   Google Scholar
• King, P.D., and Perry, M.C., 2001. Hepatotoxicity of chemotherapy. The Oncologist, 6 (2), 162–176.
   PubMed Web of Science ®Google Scholar
• Kirstein, M.N., et al., 2008. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. Cancer Chemotherapy and Pharmacology, 61 (2), 291–299.
   PubMed Web of Science ®Google Scholar
• Lauber, K., et al., 2003. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell, 113 (6), 717–730.
   PubMed Web of Science ®Google Scholar
• Manson, J.M., 1981. Developmental toxicity of alkylating agents: mechanism of action. The Biochemical Basis of Chemical Teratogenesis, 95, 136.
   Google Scholar
• Mayne, P. D., 1994. Clinical chemistry in diagnosis and treatment. 6th ed. Oxford University Press, Inc.: New York.
   Google Scholar
• Mergental, H., et al., 2005. Gemcitabine does not prevent acute rejection of the transplanted liver in rats. Transplant International, 17 (11), 687–691.
   PubMed Web of Science ®Google Scholar
• Miao, X., et al., 2016. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology, 77 (1), 181–193.
   PubMed Web of Science ®Google Scholar
• Michaelson, M.D., et al., 2015. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma. Cancer, 121 (19), 3435–3443.
   PubMed Web of Science ®Google Scholar
• Mihăilă, R.G., 2017. Liver Involvement in Hodgkin’s lymphoma: types of Injuries and therapeutic implications.‏. International Journal of Pharmacology, Phytochemistry and Ethnomedicine, 8, 1–15.
   PubMedGoogle Scholar
• Mini, E., et al., 2006. Cellular pharmacology of gemcitabine. Annals of Oncology, 17 (suppl_5), v7–v12.
   PubMed Web of Science ®Google Scholar
• Moysan, E., Bastiat, G., and Benoit, J.P., 2013. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Molecular Pharmaceutics, 10 (2), 430–444.
   PubMed Web of Science ®Google Scholar
• Nair, A.B., and Jacob, S., 2016. A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy, 7 (2), 27–31.
   PubMedGoogle Scholar
• Nakano, Y., et al., 2007. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. British Journal of Cancer, 96 (3), 457.
   PubMed Web of Science ®Google Scholar
• Nakao, K., et al., 2000. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Medical Electron Microscopy, 33 (1), 44–50.
   PubMedGoogle Scholar
• Neoptolemos, J.P., et al., 2017. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet, 389, 10073–11011.
   Web of Science ®Google Scholar
• Nyblom, H., et al., 2006. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver International : Official Journal of the International Association for the Study of the Liver, 26 (7), 840–845.
   PubMed Web of Science ®Google Scholar
• Okada, T., et al., 2011. Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer. Clinical Journal of Gastroenterology, 4 (6), 391–395.
   PubMedGoogle Scholar
• Ostruszka, L.J., and Shewach, D.S., 2003. The role of DNA synthesis inhibition in the cytotoxicity of 2′, 2′-difluoro-2′-deoxycytidine. Cancer Chemotherapy and Pharmacology, 52 (4), 325–332.
   PubMed Web of Science ®Google Scholar
• Rickenbacher, A., et al., 2011. Arguments against toxic effects of chemotherapy on liver injury and regeneration in an experimental model of partial hepatectomy. Liver International, 31 (3), 313–321.
   PubMed Web of Science ®Google Scholar
• Robinson, B.W., and Shewach, D.S., 2001. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 7 (8), 2581–2589.
   PubMed Web of Science ®Google Scholar
• Robinson, K., et al., 2003. Case report: fatal cholestatic liver failure associated with gemcitabine therapy. Digestive Diseases and Sciences, 48 (9), 1804–1808.
   PubMed Web of Science ®Google Scholar
• Seglen, P. O., 1976. Preparation of isolated rat liver cells. In: Methods in cell biology (Vol. 13, pp. 29-83). Academic press.
   Google Scholar
• Shibata, T., et al., 2016. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Cancer Science, 107 (2), 168–172.
   PubMed Web of Science ®Google Scholar
• Takasaki, K., et al., 2018. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 1, 6.
   Google Scholar
• Tate, S.C., et al., 2016. Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer. European Journal of Cancer, 66, 95–103.
   PubMed Web of Science ®Google Scholar
• Tharakan, S.T., et al., 2010. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochemical Pharmacology, 79 (2), 218–228.
   PubMed Web of Science ®Google Scholar
• Tietz, N. W., 1996. Fundementals of clinical chemistry. 4th Edition. W. B. Saunders Company, U. S. A.
   Google Scholar
• Tonato, M., Mosconi, A.M., and Martin, C., 1995. Safety profile of gemcitabine. Anti-Cancer Drugs, 6 (Supplement 6), 27–32.
   PubMed Web of Science ®Google Scholar
• USFDA 2005. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Adult Healthy Volunteer. Rockville, MD: US Food and Drug Administration.
   Google Scholar
• Wang, H., and Yadav, J.S., 2006. DNA damage, redox changes, and associated stress-inducible signaling events underlying the apoptosis and cytotoxicity in murine alveolar macrophage cell line MH-S by methanol-extracted Stachybotrys chartarum toxins. Toxicology and Applied Pharmacology, 214 (3), 297–308.
   PubMed Web of Science ®Google Scholar
• Wisher, D., 2012. Martindale: The complete drug reference. 37th ed. Journal of the Medical Library Association: Jmla, 100 (1), 75–76.
   Web of Science ®Google Scholar
• Yuan, Y., et al., 2015. Semi-mechanism-based pharmacokinetic/pharmacodynamic model for the combination use of dexamethasone and gemcitabine in breast cancer. Journal of Pharmaceutical Sciences, 104 (12), 4399–4408.
   PubMed Web of Science ®Google Scholar
• Zeiss, C.J., 2003. The apoptosis-necrosis continuum: insights from genetically altered mice. Veterinary Pathology, 40 (5), 481–495.
   PubMed Web of Science ®Google Scholar
• Zhu, X., Straubinger, R.M., and Jusko, W.J., 2015. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Journal of Pharmacokinetics and Pharmacodynamics, 42 (5), 477–496.
   PubMed Web of Science ®Google Scholar
• Ziegler, U., and Groscurth, P., 2004. Morphological features of cell death. News Physiological Science, 19 (3), 124–128.
   PubMedGoogle Scholar